Drug Discovery Services Market worth US$27.23 billion in 2030 with 10.7% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., March 25, 2025 /PRNewswire/ -- The global Drug Discovery Services Market , valued at US$14.89 billion in 2024, is forecasted to grow at a robust CAGR of 10.7%, reaching US$16.36 billion in 2025 and an impressive US$27.23 billion by 2030. Growing R&D expenditure from drug pharmaceutical and biopharmaceutical companies, the increasing R&D pipeline creating a need for increased analytical testing outsourcing, initiatives for research on rare diseases and orphan drugs, and the high cost of in-house drug development are contributing to market growth. In addition, technological advancements, the development of new drug discovery techniques, the expiration of patents, and the increasing demand for specialized testing services among end users present further avenues for growth.
Key segments positively impacting the market include chemistry services, with the largest share dominant due to technologies such as combinatorial chemistry and structure-based drug design. In the therapeutic area, the oncology segment commanded the highest market share. Pharmaceutical and biotechnology companies are the largest end users, owing to high research & development investments.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=138732129
Browse in-depth TOC on "Drug Discovery Services Market"
120 - Tables
60 - Figures
200 - Pages
By Based on Chemistry Services Segment, the market is segmented by type into chemistry services, and biology services. The chemistry services segment dominated the market in 2024. The chemistry services hold a significant share in the market owing to the introduction of technologies such as combinatorial chemistry and structure-based drug design. Rising demand for high-quality, safe, and effective drugs to support growth also support the analytical chemistry services market growth.
By Based on Biologics Segment, the drug type segment is sub-segmented into biologics and small molecules. Biopharmaceutical companies are focusing on developing biologics for various therapeutic areas, development of biologics, high cost of biologics, complexity of biologic drugs and safety and manufacturing issues related to biologics are all driving this segment growth. Biotech pharma companies are outsourcing biologic drug discovery and development to experienced service providers.
By geography, the drug discovery services market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the market due to a presence of well-established CROs, rising R&D expenditure, and rapid growth in the biosimilar and biologics markets. Asia-Pacific (APAC) is witnessing rapid growth, due to the expanding pharmaceutical and biopharmaceutical industry, the rising number of CROs, and less-stringent regulations for drug discovery processes in several APAC countries.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=138732129
The report profiles key players such as Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi AppTec (China), and Pharmaron (China), and Labcorp (US), among others.
Thermo Fisher Scientific Inc. (US):
offers a complete and integrated portfolio of discovery services. It has a strong geographic footprint and operates in more than 150 countries across North America, Europe, Latin America, and Asia. It gained over USD 14 billion in revenue in 2024 from its Life Sciences Solutions segment, which provides drug discovery services. In November 2024, the company launched a suite of expanded CRO and CDMO services under its brand- Accelerator Drug Development. In June 2024, Thermo Fisher Scientific Inc. expanded its clinical research laboratory in Wisconsin. The new 72,500-square-foot building increases the site's chemistry, manufacturing, and control (CMC) analytical capabilities as part of its clinical development and laboratory services.
Charles River Laboratories (US):
is a global drug discovery service CRO that provides a comprehensive portfolio of drug discovery and early-stage development products and services. The company has made several acquisitions, partnerships, and cooperation deals. For example, in January 2023, the company acquired SAMDI Tech, which provides label HTS solutions for drug discovery research. In January 2025, the company signed a partnership deal with NJ Bio, a CRO that provides integrated chemistry and bioconjugation services for Antibody Drug Conjugate (ADC) development from concept to clinic. The strategic alliance combines Charles River's end-to-end ADC discovery services with NJ Bio's bioconjugation and manufacturing capabilities.
WuXi AppTec (China):
has wide range of discovery and development services. China, the US, Germany, Iceland, Israel, and Korea make up the majority of its loyal customerbase. The organization prioritizes upholding service quality while promptly adjusting to transformational and innovative circumstances. To increase its capability and capacity in the worldwide market, the company concentrates on expansions. The business has expanded its capacity several times in the past four years. The corporation announced plans to invest up to USD 1.43 billion in July 2022 to build and open a new research and development and manufacturing facility in Singapore. Additionally, WuXi AppTec's Lab Testing Division (LTD) increased the toxicological capacity at the Suzhou safety assessment facility in November 2019.
Pharmaron (China):
is one of the leading players in the global drug discovery services market. Pharmaron is one of the progressive contract research organizations (CROs) that provide fully integrated services across the drug discovery and development pipeline. With expertise spanning medicinal chemistry and biology, Pharmaron supports pharmaceutical and biotech companies in accelerating new therapeutic discovery. The company's offering specially emphasizes end-to-end solutions, from target identification to preclinical candidate selection, thus making the whole process efficient. The company focuses on both organic growth and inorganic growth strategies like acquisitions and expansions for increasing its shares in the global drug discovery services market. For example, in January 2022, Pharmaron acquired the Commercial API Manufacturing Facility in the UK from Recipharm. The synergistic integration of the Cramlington Site with Pharmaron's existing service capabilities of discovery, process development, and early-stage cGMP API manufacturing at Hoddesdon will enable a complete end-to-end chemistry and manufacturing service offering in the UK.
For more information, Inquire Now!
Related Reports:
Artificial Intelligence in Drug Discovery Market
Pharmaceutical Drug Delivery Market
Therapeutic Drug Monitoring Market
Get access to the latest updates on Drug Discovery Services Companies and Drug Discovery Services Market Size
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
Share this article